Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

Cerus (CERS) will host a workshop on INTERCEPT Platelets and INTERCEPT Fibrinogen Complex at the AABB Annual Meeting on October 18, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies.

“We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences,” said Vivek Jayaraman, Cerus’ president and chief executive officer. “The meeting provides an important opportunity to share scientific data and engage with the transfusion medicine community.”

The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Eastern Time (ET).

Cerus-Sponsored Industry Workshop at AABB

• Sunday, October 18, 2026 – 1:00 p.m. - 2:00 p.m. ET. From Implementation to Impact: Real-World Experiences with INTERCEPT Platelets and IFC at Grady Health System
  (Speakers: James Sikora, MD, MPH, medical director, transfusion services, Grady Health System; Yonique Keane-Dawes, technical specialist, MLS (ASCP), Grady Health System; Lerene Archer, technical specialist, MLS (AMT), Grady Health System)
  
  A replay of the presentation will be available on Cerus’ products website approximately one to two weeks following the event at https://intercept-usa.com/.

Oral Presentations

• Session: New Insights Into Infectious Disease Detection & Elimination In Blood Donations, Saturday, October 17, 2026, 9:30 a.m. – 10:30 a.m.
  
  Bacterial Contamination of Platelets with Large Volume Delayed Sample (LVDS) Culture or Amotosalen/UVA Pathogen Reduction (PR) (Speaker: R. Benjamin)
  
  
• Session: Advancing Safety & Quality in the Transfusion Service, Monday, October 19, 8:15 a.m. – 9:15 a.m.
  
  Prospective Comparison of Pathogen-Reduced and Conventional Cryoprecipitate in Liver Transplantation (Speaker: S. Racine-Brzostek)

Poster Presentations

On display Sunday, October 18, and Monday, October 19, 2026

• Assessment of Process Performance and Product Quality When Applying a Novel Illumination Device for Pathogen Reduction of Platelets (Poster # P-BC-6)
• In Vitro Evaluation of Trima Platelets in 100% Plasma Prepared with Pathogen Reduction using an LED Illuminator (Poster # P-BC-55)
• In Vitro Evaluation of Amicus Platelets in 65% PAS Prepared with Pathogen Reduction with LED Illuminator (Poster # P-BC-54)
• In Vivo Recovery and Survival Apheresis Platelets in 100% Plasma Treated with Pathogen Reduction with LED Illuminator (Poster # P-BC-87)
• INT200 LED Illuminator for Photochemical Inactivation of Bacteria in Platelet Concentrates (Poster # P-TS-53)
• Development of the INT200 Illuminator for Photochemical Inactivation of Viruses and Parasites in Platelet Concentrates (Poster # P-TS-26)
• A Time/Motion Study to Assess Irradiated and Pathogen Reduced Platelet Component Inventory Management and Workflow at a Large Academic Medical Center in the Mid-South U.S. (Poster # P-TS-5)
• Two decades of amotosalen/UVA platelet and plasma hemovigilance in Europe (Poster # P-TS-97)
• Operational Experience With Amotosalen/UVA Pathogen Reduction for On-Demand Apheresis Platelets in Morelos, Mexico (Poster # P-IV-5)

The full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/2026-abstract-book/

Cerus representatives will be in the exhibition area at booth #915.

*Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261014682249/en/

Tim Lee – Head of Investor Relations
Cerus Corporation
ir@cerus.com
925-288-6128

Source: Cerus Corporation

Key Terms

pathogen reduction medical

Pathogen reduction is any process applied to biological materials, medical products, blood components, equipment, or surfaces that lowers the number or infectivity of disease-causing organisms (viruses, bacteria, parasites, fungi) so the material is less likely to transmit infection. Methods include physical removal (filtration), chemical or photochemical inactivation, heat, and irradiation; these processes reduce risk but do not necessarily achieve complete sterilization, and their effectiveness is judged against regulatory standards and validated test results.

cryoprecipitate medical

Cryoprecipitate is a concentrated portion of blood plasma that contains high levels of clotting proteins, produced by thawing frozen plasma and collecting the dense, protein‑rich fraction. Investors watch it because it is a critical, short‑shelf‑life medical product used to stop severe bleeding in surgery, trauma and certain disorders; its supply, manufacturing capacity, regulation and shortages can directly affect hospitals and blood‑product suppliers much like fuel availability affects airlines.

hemovigilance medical

A national or institutional surveillance system for tracking, reporting and analysing adverse events and reactions related to blood collection, processing, storage and transfusion of blood and blood products. Hemovigilance links reporting from hospitals, blood banks and manufacturers to identify safety problems, trace affected units, assess causes, and recommend changes to procedures or regulations; it is a monitoring and quality‑improvement framework rather than the clinical act of transfusing blood.

in vitro medical

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.